Novo Nordisk CEO says experimental weight loss pill could become a best in class drug

Novo Nordisk CEO Lars Fruergaard Jørgensen on Friday said the company's experimental weight loss pill, amycretin, could eventually become a best-in-class treatment for obesity. The Danish drugmaker is racing to capitalize on the runaway success of its blockbuster weight loss drug Wegovy by developing a new generation of treatments for obesity, including more convenient and potentially cheaper pills. His remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin. Pat ...